Relationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies
AffiliationUniv Arizona, Coll Med
MetadataShow full item record
PublisherNATURE PUBLISHING GROUP
CitationRelationship between physician and patient assessment of performance status and survival in a large cohort of patients with haematologic malignancies 2016, 115 (7):858 British Journal of Cancer
JournalBritish Journal of Cancer
RightsCopyright © 2016 Cancer Research UK. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.
Collection InformationThis item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at email@example.com.
AbstractBackground: Few studies have investigated the relationship between physician and patient-assessed performance status (PS) in blood cancers. Methods: Retrospective analysis among 1418 patients with haematologic malignancies seen at Dana-Farber Cancer Institute between 2007 and 2014. We analysed physician-patient agreement of Eastern Cooperative Oncology Group PS using weighted kappa-statistics and survival analysis. Results: Mean age was 58.6 years and average follow-up was 38 months. Agreement in PS was fair/moderate (weighted kappa = 0.41, 95% CI 0.37-0.44). Physicians assigned a better functional status (lower score) than patients (mean 0.60 vs 0.81), particularly when patients were young and the disease was aggressive. Both scores independently predicted survival, but physician scores were more accurate. Disagreements in score were associated with poorer survival when physicians rated PS better than patients, and were modified by age, sex and severity of disease. Conclusions: Physician-patient disagreements in PS score are common and have prognostic significance.
Note12 Month Embargo.
VersionFinal published version
SponsorsMSTAR Program (American Federation for Aging Research/NIH) [T35AG038027-05]; National Institute on Aging [T32AG000158]; Hartford Center of Excellence Award; Mary P. Murphy Fund for Hematologic Malignancies Research; Veterans' Administration Merit Review Award
Except where otherwise noted, this item's license is described as Copyright © 2016 Cancer Research UK. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License.